Sign In
Buy ADVM
$4.36
+0 (+0%)
At Close: Mar 06, 2026
Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy
02:46pm, Wednesday, 23'rd Aug 2023
14-week data from the phase 2 LUNA study, using Ixo-vec for the treatment of patients with wet age-related macular degeneration, expected in late Q3 of 2023. Preliminary safety and efficacy data from
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
08:00am, Monday, 14'th Aug 2023
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
04:05pm, Wednesday, 10'th May 2023
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly
Adverum Biotechnologies to Present at Upcoming Investor Conferences
04:05pm, Monday, 27'th Feb 2023
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
04:08pm, Friday, 04'th Nov 2022 GlobeNewswire Inc.
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in partic
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
08:05pm, Thursday, 27'th Oct 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highl
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
10:32pm, Friday, 30'th Sep 2022 PennyStocks
Hot penny stocks to watch for October.
The post Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
08:45pm, Friday, 30'th Sep 2022 GlobeNewswire Inc.
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
06:32pm, Friday, 30'th Sep 2022
Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
08:05pm, Tuesday, 27'th Sep 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for high
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
08:05pm, Friday, 23'rd Sep 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for high
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
12:00pm, Friday, 23'rd Sep 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for high
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
09:19pm, Thursday, 15'th Sep 2022 Zacks Investment Research
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
06:28pm, Thursday, 15'th Sep 2022
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08:05pm, Thursday, 08'th Sep 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for high
